1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsStephen I. Katz Early Stage Investigator Research Project Grant is sponsored by NIH. Supports innovative projects in science representing a change in research direction for early stage investigators without preliminary data.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Stephen I. Katz Early Stage Investigator Research Project Grant | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Stephen I. Katz Early Stage Investigator Research Project Grant The Stephen I.
Katz Early Stage Investigator Research Project Grant supports an innovative project in an area of science that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Each opportunity includes a table of institute-specific information, requirements and staff contacts.
The scientific contacts provided can help you determine if these opportunities are a good fit for your proposal. AIDS and AIDS-Related Applications Beginning with applications for Advisory Council Review in January 2027 (i.e., application due dates on or after May 25, 2026), NIH will no longer accept applications submitted on dedicated AIDS application due dates. ( NOT-OD-26-029 ) Dr. Stephen I.
Katz directed the National Institute of Arthritis and Musculoskeletal and Skin Diseases from August 1995 until his death in December 2018. He is remembered as an outstanding scientist, administrator, and civil servant who was committed to excellence, transparency, integrity, and public trust.
But perhaps most noteworthy were his strong commitment to mentorship, his unbridled enthusiasm, and his willingness to devote significant amounts of his time to guiding junior scientists. Based in part on his own career experiences, he frequently advocated for an NIH mechanism by which an early-stage investigator could receive support for a project unrelated to his or her area of postdoctoral study.
Dr. Katz was passionate about motivating scientists to think outside the box, and this award mechanism is intended to provide a unique opportunity for early-stage investigators to take their research in a completely new direction, thereby stimulating innovation and encouraging new approaches to solving problems. This page last updated on: February 4, 2026 For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Early stage investigators proposing innovative research projects. Confirm the full requirements in the official notice before applying.
Stephen I. Katz Early Stage Investigator Research Project Grant is funded by NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article